Stock 1BT ENLIVEX THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Enlivex Therapeutics Ltd. Deutsche Boerse AG

Equities

1BT

IL0011319527

Real-time Estimate Tradegate
Other stock markets
 11:42:21 2024-06-26 EDT 		5-day change 1st Jan Change
1.315 EUR +2.73% Intraday chart for Enlivex Therapeutics Ltd. +5.98% -46.09%
06-24 Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial MT
06-24 Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial
MT
Enlivex Therapeutics : Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating Allocetra in up to 46 Patients with Thumb Osteoarthritis
PU
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
GL
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
AQ
Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
CI
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
GL
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
AQ
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
GL
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
CI
ENLIVEX THERAPEUTICS : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K
PU
Enlivex Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
HC Wainwright Adjusts Price Target on Enlivex Therapeutics to $6 From $7, Maintains Buy Rating
MT
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
GL
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
AQ
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
CI
Enlivex Therapeutics : Immediate Report
PU
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
GL
Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall
MT
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
GL
Enlivex Therapeutics : Report of Periodic or Interim Report
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENLV Stock
  4. 1BT Stock
  5. News Enlivex Therapeutics Ltd.